Table 1.
Characteristics of the included studies
| Authors, publication year and country | Study type; Study period | Number of lesionsa | Entry criteria | Age (years)b | Basket size (mm) | Lesion size (mm)b | Guidance type |
|---|---|---|---|---|---|---|---|
| Sie et al. 2006, USA (4) | Retrospective; 2002–2004 |
742 | Breast lesions with microcalcifications | NA | 10, 15 | NA | Stereotactic |
| Killebrew et al. 2006, USA (9) | Retrospective; 2003–2004 |
800 | Mammographic lesions presenting as microcalcifications | NA | 10, 15 | NA | Stereotactic |
| Allen et al. 2011, UK (5) | Prospective; 2007-NA |
76 | Sub-centimeter breast lesions | NA | 15, 20 | 7.1 (2–10) | Ultrasound + stereotactic |
| Seror et al. 2011, France (10) | Prospective; 2008–2009 |
166 | Microcalcifications | 55.7 (31–93) | 12, 15, 20 | 8.1 (2–25) | Ultrasound + stereotactic |
| Diepstraten et al. 2011, Netherlands (11) | Prospective; 2010 |
19 | Mammographic lesions presenting as microcalcifications | 59 (37–74) | 15, 20 | 8 (2–76) | Stereotactic |
| Whitworth et al. 2011, USA (6) | Prospective; 2006–2010 |
1170 | Mammographic lesion recommended for image-guided core-needle breast biopsy | NA | 15, 20 | NA | Stereotactic |
| Razek et al. 2013, Egypt (12) | Prospective; 2012 |
80 | Small breast lesions with unclassified microcalcifications | NA (21–55) | 15, 20 | 9 (4–16) | Ultrasound + stereotactic |
| Medjhoul et al. 2013, France (13) | Retrospective; 2010–2012 |
31 | Mammographic lesions presenting as calcifications or masses | 61.2 (NA) | 12, 15, 20 | 10 (3–38) | Stereotactic |
| Al-Harethee et al. 2013, Greece (7) | Prospective; 2008–2010 |
134 | Mammographic lesions presenting as microcalcifications, solid lesions or asymmetric density | 51.3 ± 10.3 | 12, 15, 20 | NA | Stereotactic |
| Allen et al. 2014, UK (14) | Prospective; 2007–2009 |
41 | Sub-centimeter breast lesions | NA | 15, 20 | 5.7 (1–10) | Ultrasound + stereotactic |
| Al-Harethee et al. 2015, Greece (15) | Prospective; 2009–2012 |
273 | Suspicious, non-palpable mammographic lesions | 54.4 ± 10.4 | 12, 15, 20 | NA | Stereotactic |
| Scaperrotta et al. 2016, Italy (16) | Retrospective; 2010–2014 |
105 | Mammographic lesions presenting as microcalcifications measuring up to 1 cm | 55 (38–81) | 15, 20 | ≤ 10 (NA) | Stereotactic |
| Graham, 2017, USA (17) | Prospective; 2007–2014 |
461 | US visualized lesions measuring up to 2 cm | NA (23–88) | 12, 15, 20 | < 20 (NA) | Ultrasound |
| Milos et al. 2017, Austria (20) | Retrospective; 2011–2015 |
34 | Microcalcifications | 55 (31–75) | 12, 15, 20 | 8 (4–15) | Stereotactic |
| Sklair-Levy et al. 2017, Israel (21) | Prospective; 2012–2016 | 111 | Benign or atypical high-risk lesions | 50.5 (21–91) | 12, 15, 20 | < 20 (NA) | Ultrasound + stereotactic |
| Papapanagiotou et al. 2017, Greece (22) | Retrospective; 2010–2014 | 50 | Pathological diagnosis of a carcinoma lesion | 61.8 (43–80) | 12, 15, 20 | 12.7 (1.5–30) | Stereotactic |
| Niinikoski et al. 2018, Finland (23) | Retrospective; 2011–2016 | 80 | Histological or cytological and radiological suspicion of an intraductal papilloma | 60 (25–84) | 12, 15, 20 | 7 (3–16) | Ultrasound + stereotactic |
NA not available
aNumber of lesions treated with BLES procedure
bUnless otherwise stated, data are means, with ranges in parentheses